CANbridge Pharmaceuticals Inc.HKEX: 1228

Interim report 2026

· Issued by CANbridge Pharmaceuticals Inc. via HKEXnews

Filed with HKEX · Stock code 1228 · · 85 pages · English

Summary by 6ix AI

The report indicates a revenue increase attributed to sales growth from its products, Hunterase and Livmarli, despite a significant decrease in other income and gains. The company reported a loss for the reporting period, contrasting with a profit from the previous year, primarily due to reduced other income.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

CANbridge Pharmaceuticals Inc. on 6ix

Earlier from CANbridge Pharmaceuticals

Later from CANbridge Pharmaceuticals

All CANbridge Pharmaceuticals news releases